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The recent derivation of pluripotent stem cell lines from a number of different sources, including 
reprogrammed adult somatic cells, raises the issue of the developmental equivalence of these 
different pluripotent states. At least two different states representing the epiblast progenitors in 
the blastocyst and the pluripotent progenitors of the later gastrulating embryo have been recog-
nized. Understanding the initial developmental status of the different pluripotent lines is critical for 
defining starting conditions for differentiation toward therapeutically relevant cell types.Pluripotent embryonic stem (ES) cells 
are unique tools for studying mammalian 
development and differentiation in the 
Petri dish (see Review by C.E. Murry and 
G. Keller in this issue of Cell). When first 
derived from mouse blastocysts, they were 
thought to represent a self-renewing “fro-
zen in time” version of the inner cell mass 
(ICM) of the blastocyst. This is because 
ICM cells, like ES cells, are capable of 
making all somatic cell types of the mouse, 
including the germline, when returned to 
the blastocyst environment. However, in 
such chimeras, mouse ES cells do not 
contribute to the extraembryonic lineages 
of trophoblast and primitive endoderm, 
suggesting that they are pluripotent and 
not totipotent. This restriction in potency 
is identical to that of the epiblast progeni-
tors in the ICM (Chazaud et al., 2006), sug-
gesting that ES cells may represent an in 
vitro model of early epiblast development. 
More recently, pluripotent stem cell lines 
with properties similar to mouse ES cells 
have been derived from a variety of devel-
opmental stages and mammalian species, 
as well as from adult cells reprogrammed 
by ectopic transcription factors (Table 1). 
However, the relationships of all of these 
cell lines to the lineages established in the 
early embryo are not clear. By comparing 
the ability of these cell lines to differentiate 
into extraembryonic lineages and to the 
early germ layers of the embryo, I propose 
that there are at least two different pluri-
potent states represented among the cur-
rently available pluripotent stem cell lines 
and that, paradoxically, the cell lines rep-
resenting the epiblast progenitors of the 
blastocyst may be more restricted in their developmental potential than those repre-
senting the pluripotent progenitors of the 
later-stage gastrulating embryo.
Stem Cells from the Mouse 
Blastocyst
By the time of implantation, the mam-
malian blastocyst has developed three 
distinct cell lineages. An outer layer of 
trophectoderm encloses the blastocoe-
lic cavity, at one end of which is the ICM. 
The ICM consists of epiblast or primitive 
ectoderm, covered by a monolayer of 
primitive endoderm on the blastocoelic 
surface (see Figure 1). Extensive lineage 
tracing and chimera studies in the mouse 
have shown that these lineages are 
restricted in fate by the time of implanta-
tion, with the trophectoderm and primi-
tive endoderm giving rise to extraembry-
onic cell types of the placenta and yolk 
sacs and the epiblast giving rise to the 
entire fetus (Yamanaka et al., 2006). This 
restriction in lineage of the primary cell 
types is mimicked by the behavior of 
the three different self-renewing stable 
progenitor cell lines that can be derived 
from the mouse blastocyst, namely ES 
cells, trophoblast stem (TS) cells, and 
extraembryonic endoderm (XEN) cells 
(Yamanaka et al., 2006). The undifferen-
tiated ES cell state is dependent on the 
expression of a combination of transcrip-
tion factors, most notably Oct4, Sox2, 
and Nanog, and by signaling through 
the cytokine leukemia inhibitory factor 
(LIF) and bone morphogenetic protein 4 
(BMP4) (Ying et al., 2003). TS cells are 
derived from the trophectoderm, require 
expression of Cdx2, Eomes, and other 
TS-specific transcription factors, and 
depend on FGF and activin/nodal sig-
naling for self-renewal. XEN cells show 
morphological and molecular similari-
ties to primitive endoderm derivatives, 
express lineage-specific transcription 
factors, such as GATA-6 and Sox7, and 
require exogenous FGF signaling for 
their derivation, but not necessarily for 
ongoing maintenance. All three cell lines 
recapitulate the lineage of their appropri-
ate blastocyst precursor when injected 
into blastocysts to generate chimeras 
(Yamanaka et al., 2006).
Table 1. Properties of Different Pluripotent ES Cell-like Cells
Cell Line






Growth Factors for  
Self-Renewal
mES + − + LIF, BMP
mEG + ? + FGF/SCF, then LIF
mGS + ? + GDNF, then LIF
mEpiSC + + − FGF, activin
miPS + ? + LIF
hES + + na FGF, activin
hEG + ? na FGF
hEpiSC + ? na FGFCell 132, February 22, 2008 ©2008 Elsevier Inc. 527
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Interestingly, FGF signaling acting 
through the canonical Ras-MAPKinase 
pathway seems to play opposing roles 
in ES cells versus TS cells, promoting 
differentiation in ES cells and prolifera-
tion in TS cells. ES cells lacking FGF4 
or Erk2 are resistant to differentiation 
and maintain expression of pluripo-
tent markers, suggesting that there is 
an autocrine action of FGF in prepar-
ing ES cells for differentiation (Kunath 
et al., 2007; see Essay by J. Silva and 
A. Smith in this issue). Conversely, TS 
cells require exogenous FGF signaling 
through the ERK pathway for mainte-
nance of their self-renewal; blocking the 
FGF signaling pathway leads to their dif-
ferentiation into trophoblast giant cells 
(Rossant, 2001). These different roles 
for FGF signaling reflect the in vivo roles 
of FGF signaling in early development. 
FGF signaling is required to maintain 
proliferation of the early postimplanta-
tion trophoblast, as well as to promote 
differentiation of the epiblast. Although 
ES cells do not readily generate tropho-
blast under normal culture conditions, 
they can be transformed into functional 
TS cells by conditional deletion of the 
Pou5f1 gene (which encodes the Oct4 
protein) or by overexpression of Cdx2 (a 
caudal-related homeodomain transcrip-
tion factor) and transfer to TS culture 
conditions (Niwa, 2007).
Based on the lineage restriction of 
mouse ES, TS, and XEN cells in chime-
ras and other properties, we have pro-
posed that these cell lines represent the 
three restricted lineages known to exist 
by implantation in the mouse blastocyst. 
Implicit in this proposal is that manipu-
lating the differentiation of ES cells into 
later cell types will require mimicking the 
phases of early axis formation, followed 
by germ layer development, before spe-
cialized cell types can be obtained.
Do Human Blastocyst-Derived Stem 
Cells Obey the Same Rules?
Primate blastocysts prior to implantation 
are very similar in structure to rodent 
blastocysts, although cell number is 
higher and postimplantation morphol-
ogy is different. Although the morphol-
ogy of the cell lineages of the primate 
blastocyst is similar to that of the rodent, 
there could be differences in timing 
of lineage restriction, given the longer 
period of time before implantation (7–10 
days versus 4 days in mouse). When ES 
cells were first derived from human blas-
tocysts, they were shown to possess 
many of the properties found in mouse 
ES cells. These properties include 
expression of Oct4, Sox2, and Nanog 
and pluripotency (demonstrated in vitro 
and when the human ES cells were 
transplanted to ectopic sites in mouse 
where they formed teratomas) (Thom-
son et al., 1998). However, the genome-
wide transcriptional profiles of human 
and mouse ES cells show many differ-
ences, and there is limited overlap in the 
downstream targets of Oct 4 and Sox2 
as defined by genome-wide ChIP analy-
sis (Boyer et al., 2005; Loh et al., 2006). 
The significance of these differences 
should not be overstated as the studies 
were performed on different technology 
platforms and under different culture 
conditions. However, they are intriguing, 
especially when combined with evidence 
that the signaling pathways supporting 
self-renewal may also differ. LIF signal-
ing does not support self-renewal of 
human ES cells, whereas BMP actively 
promotes their differentiation. A combi-
nation of FGF and activin/nodal signal-
ing maintains self-renewal of human ES 
cells under serum-free conditions (Vallier 
et al., 2005). These are exactly the con-
ditions that promote TS cell not ES cell 
development from the mouse blastocyst 
and drive differentiation of mouse ES 
cells (Kunath et al., 2007). Human ES cell 
cultures have been reported to contain 
cells with trophoblast-like expression 
patterns (Thomson et al., 1998, Xu et 
al., 2002). However, stable proliferating 
TS cell lines have not yet been reported 
either directly from human blastocysts 
or from ES-cell derived trophoblast 
cells. The reason may lie in the behavior 
of human trophoblast cells around the 
time of implantation, where there is rapid 
formation of a nonproliferating syncy-
tiotrophoblast that mediates attachment 
and invasion of the uterine epithelium. 
Only at later stages does the trophoblast 
show extensive proliferation to form the 
chorionic villi. Thus, the blastocyst may 
not be the appropriate stage to obtain 
FGF-responsive proliferating TS cells.
Human ES Cells and EpiSCs: Defin-
ing a Common Epiblast Cell State
Clearly, there are distinct differences 
between mouse and human ES cells, 
despite their common properties of Oct4 
expression, ease of self-renewal, and 
pluripotency. On the face of it, the sim-
plest explanation would be that human 
ES cells are in a pre-epiblast stage of 
commitment, where all lineage path-
ways including trophoblast are still open, 
whereas mouse ES cells represent the 
Figure 1. Implantation of the Human Blastocyst
Shown is the human blastocyst prior to implantation (left) and the human conceptus shortly after implan-
tation as gastrulation begins (right). The inner cell mass (ICM) of the blastocyst forms the epiblast of the 
germ disc, which is underlain by the primitive endoderm. As gastrulation begins, the primitive streak in 
the middle of the disc generates a mesoderm layer that separates the epiblast and primitive endoderm. 
Definitive endoderm will also be generated to replace the primitive endoderm. The trophectoderm of 
the blastocyst produces invasive syncytiotrophoblasts that promote the attachment and invasion of the 
conceptus into the uterine wall.
already lineage-restricted epiblast pro-
genitor of the blastocyst. This difference 
could relate to the slower pace of lineage 
restriction in the early stages of human 
development compared with mouse. 
However, recent work has suggested 
a different explanation. Two groups 
derived pluripotent cell lines, termed 
EpiSCs, directly from the early postim-
plantation epiblast in the mouse (Brons 
et al., 2007; Tesar et al., 2007). These 
cell lines still depend on the standard 
pluripotency transcription factors, Oct4, 
Sox2, and Nanog, but proliferate in the 
presence of FGF and activin rather than 
LIF. EpiSCs were able to generate tissues 
from all three germ layers in vitro and 
to form teratomas. However, they were 
unable to contribute to normal tissues in 
mouse chimeras. Whether this is due to 
a true developmental block or a cellular 
incompatibility between EpiSCs and the 
host embryo, such that the EpiSCs fail to 
integrate into the host ICM, is currently 
unclear. As well as requiring the same 
growth factors for self-renewal as human 
ES cells, EpiSCs were also reported to 
show gene expression profiles and 
transcription factor networks closer to 
human ES cells than to mouse ES cells. 
Interestingly, like human ES cells, EpiSCs 
could express markers of trophoblast 
and primitive endoderm when treated 
with BMP4 (Brons et al., 2007).
The similarities between human ES 
cells and mouse EpiSCs have led to 
the suggestion that human ES cells are 
actually equivalent to the early postim-
plantation epiblast, rather than its ICM 
progenitor. Data mining of the depos-
ited gene expression arrays for EpiSCs 
shows that they do express pluripotent 
markers but also seem to be expressing 
higher levels of mesoderm and definitive 
endoderm transcripts as compared to 
mouse ES cells (B. Cox and J.R., unpub-
lished data). This suggests that EpiSCs, 
and by extension human ES cells, may 
be in an unusual transition state that is 
perhaps more equivalent to a primitive 
streak progenitor: poised on the verge 
of differentiation into multiple directions. 
Consistent with this possibility, FGF and 
activin play roles in both proliferation 
and differentiation of the postimplanta-
tion epiblast in vivo. However, primitive 
streak cells would be expected to be 
even less likely to differentiate into extra-embryonic lineages, the trophoblast 
and primitive endoderm, than the earlier 
epiblast progenitors of the blastocyst. 
And yet both human ES cells and mouse 
EpiSCs have been reported to have 
this property. This paradox is not easily 
resolved by embryological comparisons 
and suggests that the process of gener-
ating permanent self-renewing cell lines 
may change the epigenetic environment 
and open up pathways of differentiation 
not normally revealed in vivo. Because 
FGF and activin, the factors used to pro-
mote human ES cell self-renewal, also 
promote TS cell self-renewal, any ten-
dency toward trophoblast differentiation 
in human ES cells or mouse EpiSCs will 
be accentuated by expansion of these 
cells. Conversely, in mouse ES cells, FGF 
treatment drives extensive differentia-
tion, such that formation of any tropho-
blast cell would probably be missed. In 
fact, mouse ES cells have been reported 
to generate some trophoblast differen-
tiation under certain culture conditions 
(Schenke-Layland et al., 2007).
The Growing List of ES Cell-like 
Cells
The first pluripotent stem cell lines to 
be isolated were embryonal carcinoma 
(EC) cells derived from multilineage 
tumors known as teratocarcinomas 
(Solter, 2006). Spontaneous teratocar-
cinomas can arise in the adult testis or 
ovary of mice or humans. They can also 
be produced experimentally by grafting 
early mouse embryos to ectopic sites. 
Although EC cells can make chimeras, 
contributions are often low, germline 
transmission has never been consis-
tently reported, and chimeras often 
develop EC-derived tumors. Whether 
these properties are more similar to ES 
cells or EpiSCs is not really clear. EC 
cell lines, like P19, which were derived 
from ectopic grafts of postimplantation 
embryos, might be closer to EpiSCs than 
to mouse ES cells. How much of the vari-
able properties of mouse EC cells relates 
to possible differences in lineage origin 
and how much to the known karyotypic 
anomalies of these cells is unclear.
Importantly, it seems that all the 
stages of development from which it is 
possible to derive teratocarcinomas can 
also give rise to ES cell-like pluripotent 
cells directly in vitro. The first ES cell-like Cell 132,cells to be derived from nonblastocyst 
sources were mouse and human EG cells, 
which are derived from primordial germ 
cells in the developing gonad (Matsui et 
al., 1992; Resnick et al., 1992; Shamblott 
et al., 1998). In the mouse, these cells 
behave like ES cells in their pluripotent 
capacity but have imprinting differences 
that relate to their germ cell origin. Initial 
cultures of primordial germ cells (PGCs) 
in both mouse and human require FGF 
signaling for proliferation, but established 
EG cultures seem to respond to growth 
factor signaling in a similar manner to the 
ES cells of the appropriate species. The 
epiblast-like properties and the extraem-
bryonic potential of mouse and human 
EG cells have not been extensively stud-
ied, making it unclear whether they show 
the same potential lineage differences as 
mouse and human ES cells.
Three groups have reported the deri-
vation of pluripotent ES cell-like cells 
from the adult or neonatal mouse testis 
(Guan et al., 2006; Kanatsu-Shinohara 
et al., 2004; Seandel et al., 2007). After 
initial expansion of spermatogonial 
stem cells in the growth factor GDNF, a 
few colonies resembling ES cells were 
observed and could be expanded in LIF 
into permanent cell lines. These multi-
potent germline stem (mGS) cells, when 
derived from the neonatal testis, were 
fully pluripotent as judged by somatic 
and germline chimerism after blastocyst 
injection and are assumed to be ES cell-
like rather than EpiSC-like. Interestingly, 
Shinohara and colleagues reported that 
epiblast-like colonies were also observed 
in the spermatogonial cultures (Kanatsu-
Shinohara et al., 2004), raising the ques-
tion of whether EpiSCs could also be 
obtained if cultures were supplemented 
with FGF and activin.
When considering all of these ES cell-
like cells, there is simply not enough data 
available to assess whether they all fall 
into the two proposed pluripotent states, 
ES cell-like and EpiSC-like, or, indeed, 
whether other pluripotent states exist. It 
is clear that only cells that express Oct4 
and have the potential to form germ 
cells or are germ cells themselves can 
give rise to pluripotent cell lines directly. 
Although germ cells develop as a small 
group of cells in the posterior of the 
primitive streak, the entire epiblast up 
until that time is thought to have germ  February 22, 2008 ©2008 Elsevier Inc. 529
cell potential. Once Oct4 is downregu-
lated and germ cells are set aside, the 
epiblast loses the capacity to make germ 
cells and to make teratocarcinomas. One 
would predict that the ability to generate 
EpiSCs from epiblast would similarly be 
lost concomitant with germ cell segrega-
tion, a testable hypothesis. Whether there 
is a special epigenetic state associated 
with pluripotency, perhaps related to this 
germ cell potency, is a subject of much 
current research. However, the overriding 
importance of the key transcription fac-
tors, Oct4 and Sox2, for driving pluripo-
tency is supported by the recent deriva-
tion of ES cell-like cells, called iPS cells, 
from mouse (Takahashi and Yamanaka, 
2006; Maherali et al., 2007: Okita et al., 
2007: Wernig et al., 2007) and human 
fibroblasts (Takahashi et al., 2007; Yu et 
al., 2007). Reprogramming of the adult 
cells was achieved by retroviral expres-
sion of a set of exogenous transcription 
factors, which must always include Oct4 
and Sox2, as well as factors to promote 
cell proliferation (see Review by R. Jae-
nisch and R. Young in this issue). Exactly 
the same set of transcription factors—
Oct4, Sox2, Klf4, and c-Myc—were able 
to induce the formation of iPS cells from 
mouse and human adult somatic cells 
(Takahashi et al., 2007; Takahashi and 
Yamanaka, 2006), but the growth factor 
conditions required for expansion were 
clearly different. Human iPS cells could 
be expanded in FGF but not in the pres-
ence of LIF, whereas mouse iPS cells 
required LIF. Not reported is whether 
mouse reprogrammed cells can be 
expanded into an EpiSC-like cell in the 
presence of FGF and activin.
The Developmental State of ES 
Cell-like Cells
There is now a growing array of mouse 
and human cell lines with pluripotent 
capacity, but their relationship to each 
other and to their lineage progenitors 
in the embryo is less than clear. In the 
mouse, ES cells are well characterized 
and their full pluripotency can be proven 
by analysis of chimeras. ES cell-like cells 
generated from the testis and by repro-
gramming of adult fibroblasts have also 
been shown to possess full pluripotency, 
including germline contribution in chi-
meras. However, the growth factor con-
ditions used to maintain mouse ES cells 530 Cell 132, February 22, 2008 ©2008 Elseand ES cell-like cells seem to be pecu-
liar to the mouse. It has not proven pos-
sible to isolate fully pluripotent ES cells 
directly from the blastocyst of any other 
mammalian species, including the rat, 
even in the presence of LIF. Further, the 
LIF/JAK/STAT signaling pathway does 
not appear to be required in vivo for nor-
mal epiblast development. Instead, it 
plays a special role in delayed implanta-
tion, promoting epiblast survival (Nichols 
et al., 2001). Exogenous LIF may thus be 
a very potent inhibitor of the differentia-
tion pathway toward the postimplanta-
tion epiblast that would be the normal 
fate of the epiblast progenitors in the 
ICM. In species that lack mechanisms to 
delay implantation, this pathway may not 
be available for preserving the epiblast 
progenitor as an ES cell-like cell. On the 
other hand, the growth factor conditions 
including FGF and activin that are used 
to maintain self-renewal of human ES 
cells and mouse EpiSCs may reflect con-
served pathways involved in germ layer 
development in all vertebrate species. 
This raises the possibility that EpiSC-
like cells may be a more common form 
of pluripotent progenitor across different 
species. Indeed, it has been reported 
that rat EpiSCs can be readily derived 
under the same conditions as mouse 
EpiSCs (Brons et al., 2007). It remains to 
be seen whether non-LIF-mediated con-
ditions can be found that promote the 
proliferation of cells equivalent to mouse 
ES cells from other species. Further 
detailed comparison of the developmen-
tal potential of all the different ES cell-like 
cells in terms of their spontaneous differ-
entiation into extraembryonic cell types, 
their responses to ectopic expression of 
extraembryonic lineage-specific tran-
scription factors, and their responses to 
changing the growth factor environment 
should help to clarify the developmental 
equivalence of each cell type.
Knowledge of the initial developmental 
state of the different pluripotent cell lines 
is not just a matter of biological curiosity. 
Responses to differentiation protocols 
will vary according to where the cells sit 
in a developmental hierarchy. Protocols 
developed in mouse ES cells may not be 
easily transferable to human ES cells if 
they are nonequivalent in developmental 
status. It is likely that mouse ES cells have 
to be differentiated through an epiblast/vier Inc.primitive streak stage first, before defini-
tive germ layer differentiation, whereas 
human ES cells may already be at this 
transitional stage. Mouse EpiSCs and 
human ES cells, for example, express 
some markers typical of definitive endo-
derm and may be easier to drive toward 
this therapeutically important cell lineage 
compared with mouse ES cells, which 
tend toward differentiation into primitive 
endoderm. The possibility that there is 
more than one pluripotent ES cell-like 
state becomes even more important to 
understand in the context of reprogram-
ming adult cells to pluripotency. Under-
standing the different pathways that can 
lead to reprogramming should help to 
clarify the range of different pluripotent 
states.
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